Psychiatry · Medical Literature
[Correspondence] Culturally specifying placebo and nocebo effects
Abstract
Matthew J Burke and colleagues,1 and the accompanying Editorial,2 rightly argue that placebo and nocebo effects should no longer be treated as nuisance factors, but as pervasive mechanisms that psychiatry should understand and harness. Burke and colleagues’ emphasis on expectancy, therapeutic context, and ethical clinical application is especially timely as psychiatric treatments become more complex and procedurally intensive.
Clinical relevance
Do the frameworks for understanding placebo and nocebo effects proposed by Burke and colleagues adequately account for cultural specificity in shaping patient expectations, therapeutic context, and the clinical expression of these effects in psychiatry? __SNAPSHOT__ {"studyDesign":"Correspondence (letter to the editor); not an original empirical study. No primary data collected.","setting":"Not reported; published in The Lancet Psychiatry in response to a two-part review series on reconceptualising placebo and nocebo effects in psychiatry.","sampleSize":"Not applicable (correspondence/commentary; no patient-level data)","population":"Not applicable; the letter addresses conceptual gaps relevant to all psychiatric patient populations, particularly those from non-Western or culturally diverse backgrounds who may be underrepresented in placebo/nocebo research.","intervention":"Not applicable; the correspondence advocates for the integration of cultural variables (e.g., cultural context, culturally specific expectations, and healing rituals) into frameworks for understanding and applying placebo and nocebo effects.","comparator":"Not applicable","primaryOutcome":"Not applicable; the correspondence advances a conceptual argument that placebo and nocebo effects are culturally specified and that Burke et al.'s framework should explicitly incorporate cultural moderators.","followUp":"Not applicable","fundingSource":"Not reported"}
Key findings
This is a correspondence letter, not an empirical study; no primary outcome data, effect sizes, p-values, confidence intervals, or NNT/NNH are reported or calculable. Kotera endorses Burke and colleagues' central thesis — that placebo and nocebo effects are pervasive, neurobehaviorally meaningful mechanisms that psychiatry should understand and harness rather than dismiss — and extends their argument by raising the concern that cultural context is insufficiently specified in the proposed framework. The author argues that expectancy, therapeutic alliance, and the meaning of treatment are not culturally invariant, and that strategies for harnessing placebo effects or mitigating nocebo effects may differ substantially across cultural groups. No adverse events are reported. The correspondence situates itself within a body of established literature demonstrating that treatment rituals, clinician-patient communication styles, and belief systems all vary by culture and shape placebo and nocebo responses. No new quantitative data are presented.
Practice implications
This correspondence does not establish new clinical evidence; it identifies a conceptual gap in an influential two-part Lancet Psychiatry review (Burke et al., 2026, pp. 413–440) that argued for reconceptualising placebo and nocebo effects as therapeutic tools in psychiatry. Kotera's core argument — that these effects are culturally specified and cannot be applied uniformly across diverse patient populations — is conceptually well-grounded and clinically important, particularly as psychiatric practice becomes more procedurally intensive and globally diverse. However, no empirical data are presented to quantify how much cultural factors moderate placebo or nocebo magnitudes in specific psychiatric conditions, and no clinical recommendations are operationalised. The findings of Burke et al. — including placebo-arm remission rates approaching 50% in device-based depression trials, nocebo-attributed side effect rates of 44.7% in antidepressant arms and 68% in antipsychotic arms — apply primarily to populations enrolled in predominantly Western clinical trials and may not generalise to patients from non-WEIRD (Western, Educated, Industrialised, Rich, Democratic) backgrounds. The letter appropriately flags a limitation of the Burke et al. framework without undermining its core validity. Only the abstract of the Kotera correspondence was available for review; the full text, including any specific cultural examples or proposed remedies, could not be assessed. __LIMITATIONS__ Only an abstract of the Kotera correspondence was available; the full text and any specific arguments, citations, or cultural examples cannot be evaluated.,As a correspondence letter, no original empirical data are presented; all arguments are conceptual and therefore cannot be graded for evidence quality.,No specific cultural groups, psychiatric conditions, or clinical contexts are named in the available abstract, making it impossible to assess the specificity or actionability of the claims.,The correspondence does not propose operationalised, testable hypotheses or interventions, limiting its direct translational value.,The parent review articles (Burke et al.) to which Kotera responds are accessible only in paywalled form; independent verification of their reported statistics relied on secondary sources and is noted accordingly.,The relationship between cultural variables and placebo/nocebo magnitude in psychiatry remains poorly characterised in the empirical literature; Kotera's argument, while plausible, is not yet supported by a systematic evidence base.,A PMID was not assigned to the Kotera correspondence at the time of submission, limiting traceability and citation. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ Kotera's correspondence raises a clinically important and underaddressed concern: that placebo and nocebo effects are culturally specified, and that strategies for harnessing or mitigating them must account for patients' cultural context, belief systems, and healing expectations. While Burke et al.'s framework represents a meaningful advance for psychiatry, clinicians applying these principles should be cautious about assuming uniform applicability across culturally diverse patient populations. Further empirical work is needed to characterise how culture moderates placebo and nocebo magnitudes across specific psychiatric conditions before culturally adapted clinical protocols can be developed.